Inactive Instrument

Press Releases Protagonist Therapeutics Inc Nasdaq

Equities

US74366E1029

End-of-day quote Nasdaq Other stock markets
- ^PTS	-

Apr. 03	Protagonist Therapeutics Insider Sold Shares Worth $707,750, According to a Recent SEC Filing	MT
Mar. 26	Protagonist Therapeutics, Inc. Provides Update on Verify Patient Enrollment and Timing of Top-Line Data	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Protagonist Therapeutics Provides Update on VERIFY Patient Enrollment and Timing of Top-line Data	Mar. 27	AQ
Protagonist Therapeutics: Q4 Earnings Snapshot	Feb. 27	AQ
Protagonist Therapeutics to Participate in Fireside Chat at Guggenheim Healthcare Talks 2024	Jan. 30	AQ
Protagonist Reports 2-Year Follow Up Data from Rusfertide REVIVE Study at the ASH Annual Meeting Showing Durable Efficacy and No New Safety Signals	Dec. 13	AQ
Protagonist Announces Two New Phase 3 ICONIC Studies in Psoriasis Evaluating JNJ-2113 in Head-to-Head Comparisons with Deucravacitinib	Nov. 28	AQ
Protagonist Therapeutics: Q3 Earnings Snapshot	Nov. 02	AQ
Protagonist Announces Advancement of JNJ-2113 across Multiple Indications	23-10-10	AQ
Protagonist Therapeutics to Present at Upcoming Investor Conferences	23-09-06	AQ
Protagonist Receives $34 Million from Warrant Exercises	23-08-10	AQ
Protagonist Therapeutics Reports Granting of Inducement Award	23-07-19	AQ
Protagonist Reports Positive Results from Phase 1 and Pre-clinical Studies of Oral Interleukin-23 Receptor Antagonist JNJ-2113	23-05-15	AQ
Protagonist Reports Positive Results from Phase 1 and Pre-clinical Studies of Oral Interleukin-23 Receptor Antagonist JNJ-2113	23-05-12	PR
Protagonist Therapeutics to Participate in the JMP Securities Life Sciences Conference	23-05-11	PR
Protagonist Therapeutics Announces Presentations at the 2023 Annual Congress of the European Hematology Association	23-05-11	PR
Protagonist Therapeutics: Q1 Earnings Snapshot	23-05-04	AQ
PROTAGONIST THERAPEUTICS, INC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	23-05-04	AQ
Protagonist Reports First Quarter 2023 Financial Results and Provides Corporate Update	23-05-04	PR
Protagonist Therapeutics : Underwriting Agreement - Form 8-K	23-04-10	PU
PROTAGONIST THERAPEUTICS, INC : Other Events, Financial Statements and Exhibits (form 8-K)	23-04-10	AQ
PROTAGONIST THERAPEUTICS, INC Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)	23-03-15	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Protagonist Therapeutics Inc Nasdaq

Equities

US74366E1029

Press Releases

Filters